Omeros feels the pain of public late-stage failure

Date April 01, 2011

A mere 18 months after floating on the Nasdaq stock exchange, Omeros is experiencing the full pain of a late-stage clinical set back as a public company. News that its lead product failed a phase III trial sent shares in the company plunging 40% this morning, to $4.85.

This means Omeros' value has halved since it floated at $10 per share back in October 2009. Few companies have managed to achieve a market listing in the last couple of years and even fewer have maintained their flotation price (Anthera listing confirms weak IPO market, March 5, 2010). This news – which at best means a big delay for Omeros’ lead product and probably another fundraising - will not help any other IPO hopefuls courting a still sceptical public investor base.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd